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ABSTRACT 
 Our bodies produce free radicals that are required for regular physiological functions but 
are harmful when present in excess. There’s compelling evidence on the link between these 
radicals and neurodegenerative diseases. Normally, the body can counteract excess free radicals, 
but that’s not always sufficient, and using exogenous antioxidants may be a necessity. For 
instance, flavonoids from food have been heavily investigated for their roles as antioxidants, and 
among them, flavones show great promise to scavenge free radicals.  
     Fluorination of biologically active compounds is a strategy to improve their properties for 
drug development. Research continues to show how incorporating fluorine atoms can enhance 
potency, reduce undesired metabolic pathways, and alter physicochemical properties of 
compounds. Moreover, fluorinated molecules can be observed, and their activities can be 
quantified by utilizing 19F NMR.  
 Herein, we propose a synthesis for polyhydroxylated 3-methoxyflavones and their 
trifluoromethylated derivatives. During the synthesis, the structures will be characterized using 
1H and 13C NMR, and 2D NMR. The compounds will be tested for their radical scavenging 
activities by using the 2,2-diphenyl-1-picrylhydrazyl-hydrate radical scavenging assay, and their 
neuroprotective effects will be analyzed. The effect of adding trifluoromethyl groups will be 
evaluated, and the antioxidant activities of the trifluoromethylated derivatives will be observed 
and quantified using 19F NMR. 
 The total synthesis of polyhydroxylated flavones have proven to be challenging, due to 
the presence of more than one hydroxyl group. Direct cyclization was not successful in any of 
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the attempts. However, by using a silyl protecting group, the cyclization was feasible. Other 
reactions like the Friedel-Crafts acylation and selective protection of phenols were also difficult.  
 Flavones are efficient antioxidants, and modified derivatives can be promising to fight 
neurodegenerative diseases. We propose a synthesis of 3-methoxyflavones and their 
trifluoromethylated derivatives for such a purpose. After the completion of the synthesis, the 
compounds will be tested, their activities will be quantified, and the effect of 
trifluoromethylation will be determined. 
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1. INTRODUCTION 
 Even though the human body demands oxygen and utilizes reactive oxygen species to 
function properly, the presence of the latter in excess can have negative effects on the body.1 
Such species can damage tissues, enzymes, cell membrane lipids, carbohydrates, and DNA, 
causing protein modifications and membrane or DNA damage.2 These reactive oxygen species 
can give rise to free radicals, which have a unique property of having an unpaired electron.1 The 
body can counteract such species enzymatically by using superoxide dismutase, catalase, and 
glutathione peroxidase.3 Non-enzymatic mechanisms are also utilized, which involve the use of 
compounds such as glutathione, ascorbic acid, and a-tocopherol.3 However, when the body fails 
to regulate the presence of free radicals, oxidative damage might occur in many tissues, 
including neurons, contributing to the development of neurodegenerative diseases.1, 4 Therefore, 
we can utilize antioxidants as an efficient and straightforward method to protect neurons from 
oxidative stress. 
 
1.1. Flavonoids 
 Flavonoids are naturally occurring compounds generated through the secondary 
metabolism of plant species.5 They can be found in fruits, vegetables, tea, beer, wine, and 
coffee.5 They possess the low molecular weight 2-phenylchromane skeleton, containing rings A, 
B, and C (Fig. 1).6 Moreover, these compounds were sub-classified into flavonols, flavones, 
flavanones, flavonoid glycosides, flavonolignans, flavans, isoflavones, anthocyanidins, aurones, 
leucoanthocyanidins, neoflavonoids, and chalcones.5
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Figure 1. The basic skeletons of flavonoids and flavones.5, 6  
 
 Flavonoids are best known for their antioxidant and neuroprotective effects in diseases 
involving an oxidative stress component, i.e. neurodegeneration, atherosclerosis, cancer, and 
diabetes, warranting the heavy investigation of these compounds in drug discovery.5 When 
looking at activities of the flavonoid sub-classes, flavones are thought to be one of the most 
powerful acting as antioxidants.3 Several mechanisms have been proposed as to how flavonoids 
act as antioxidants, and a major pathway is the direct scavenging of free radicals.3 During this 
process, hydroxyl groups on flavonoids will donate a proton to the radical, through homolytic 
cleavage, to produce an inactive radical (Fig. 2).7 For efficient radical scavenging activity, three 
main structural features must be present.8 For electron delocalization, ring B should be a catechol 
or catechol-like, and ring C must have a double bond between C2-C3 that is conjugated with the 
ketone at position 4.8 For hydrogen bonding to the ketone at position 4, ring C should have 
hydroxyl groups on C3 and C5.8  
 
 
Figure 2. The structure-activity relationship for direct radical scavenging activity of flavonoids 
and its mechanism.2  
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1.2. 3-Methoxyflavones 
 In one study, 3-methoxyflavone derivatives were synthesized and tested for their 
activities as antioxidants.9 Several compounds had substituents on rings A and B such as 
hydroxyl groups, methoxy groups, or hydrogen atoms (Fig. 3). The IC50 (µg/mL) for each 
compound was measured in the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay, 
and vitamin C was used as a reference (Table 1). The findings indicated that the compounds 
must contain at least two hydroxyl groups on ring B and a C7-O-R for good antioxidant activity.9  
 
 
Figure 3. 3-Methoxyflavone derivatives from the literature.9  
 
Table 1. The antioxidant activities of the synthesized 3-methoxyflavones.9  
Compound DPPH IC50 (µg/mL) Compound DPPH IC50 (µg/mL) 
 
> 50 
 
4.91 ± 0.48 
 
3.76 ± 0.22 Vitamin C 5.07 0.73 
 
1.3. Synthesis of Flavones 
 There are numerous ways to synthesize flavones, and they have been categorized into two 
methods based on the key intermediate involved, either a b-diketone or a chalcone 
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intermediate.10 Both intermediates are synthesized by using o-hydroxyacetophenones as starting 
materials, but the b-diketone pathway is more commonly used.10 To synthesize a flavone 
(Scheme 1), an o-hydroxyacetophenone is acylated by using a base, in which the Baker–
Venkataraman rearrangement occurs to produce the b-diketone intermediate (Fig. 4).10 Next, the 
intermediate undergoes acid-catalyzed cyclodehydration to produce the flavone.10  
 
 
Scheme 1. A typical synthesis of flavones.10  
 
 
Figure 4. The Baker–Venkataraman rearrangement.10 
 
1.4. Fluorine Atoms in Medicinal Chemistry 
1.4.1. Fluorine Atoms in Drug Discovery 
 The introduction of fluorine atoms in molecules can enhance their physicochemical 
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undesired metabolic pathways, alter lipophilicity, and restrict conformation.11 The 
electronegativity of fluorine atoms can alter the acidity or basicity of nearby functional groups.11 
Furthermore, fluorine can act as a bioisostere for many moieties, including a hydrogen atom, a 
carbonyl group, and a sulfonyl group.12  
 Metabolic pathways of drugs are often altered to achieve specific goals, like enhancing 
the metabolism of a compound that accumulates or reducing the metabolism of a compound that 
is rapidly cleared from the body. Fluorine atoms have been repeatedly utilized for the latter. For 
instance, when dealing with aromatic rings, introducing a CF3 functionality in place of a methyl 
group (Table 2), or an Ar-F in place of an Ar-H, proved to reduce undesirable metabolic 
pathways.11, 13 Such effects on metabolism may be attributed to the stability of the C-F bond, in 
comparison to a C-H bond, these bonds have a strength of 116 kcal/mol and 99 kcal/mol, 
respectively.14  
 
Table 2. The effect of exchanging a CH3 group with a CF3 group on metabolic stability.13  
Compound R HLM Clint (µl/min/kg) 
 
CH3 87.9 
CF3 44.7 
 
CH3 168 
CF3 46 
HLM Clint is the intrinsic clearance in human liver microsomes. 
 
1.4.2. Fluorinated Compounds in the Market 
 Fluorinated compounds are among the top-selling drugs on the market, and about 30% of 
all newly approved drugs are fluorinated.15 When looking at the three biggest blockbuster drugs 
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of all time, the mono-fluorinated Lipitor® is the highest ranking, with lifetime sales of almost 
$150.1 billion.16 Advair® comes in the third place, containing the tri-fluorinated compound 
fluticasone, and lifetime sales of $95.7 billion.16 Moreover, when analyzing the 2016 top two 
hundred pharmaceutical products by retail sales list, fluorinated compounds make up about 28% 
of the small molecule population, in which about 9% contain at least one trifluoromethyl group.17 
Six of the top ten small molecule drugs in the list are fluorinated, Harvoni®, Advair®, Sovaldi®, 
Januvia®, Truvada®, and Crestor® (Fig. 5).17 The total sales of the six compounds in 2016 were 
around $28.278 billion.17  
 
 
Figure 5. Structures and indications of high-selling fluorinated drugs.16, 17  
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1.4.3. Fluorine Atoms as 19F NMR Probes     
 Fluorine has another beneficial property that is widely overlooked, it can serve as a 19F 
NMR probe. Such probes can be utilized to assess drug interactions and metabolic/biological 
processes of molecules. In one study, 19F NMR probes of the natural product, parthenolide, were 
created to gather mechanistic data.18 Prodrugs of parthenolide were synthesized so that the active 
form of the drug is released from a trifluoromethylated amine.18 The activity of such compounds 
was quantitatively analyzed using 19F NMR, in which data were rapidly acquired with high 
sensitivity due to the presence of a trifluoromethyl group.18 Moreover, such data provided 
information on the effect of the presence of glutathione on the activation of the prodrug (Fig. 
6A), where the trifluoromethylated amine was seen in a higher concentration in the presence of 
glutathione, and in a lower concentration in its absence (Fig. 6B and 6C).18 Concentrations were 
measured using quantitative NMR.18  
 
 
Figure 6. The parthenolide prodrug and 19F NMR for the prodrug in: A) Absence of glutathione, 
B) Presence of glutathione.18  
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1.5. Synthetic Strategy 
 Herein, we attempt the synthesis of several 3-methoxyflavone derivatives 1–12 (Fig. 7), 
of which compounds 4–12 will have trifluoromethyl groups. The compounds will be tested for 
their potential antioxidant and neuroprotective activities. Since the trifluoromethyl group is much 
more sensitive to 19F NMR than a fluorine atom, these trifluoromethylated compounds will be 
used as 19F NMR probes for quantitative analysis of their radical scavenging properties. 
 
 
Figure 7. The proposed 3-methoxyflavone derivatives. 
 
 The retrosynthesis analysis shows the initial synthetic plan for all compounds (Scheme 
2). The phenolic flavones 2, 5, 8, and 11 will be synthesized from their benzylated derivatives 1, 
4, 7, and 10, respectively. Both the benzylated and the trimethoxylated flavones 1, 3, 4, 6, 7, 9, 
10, and 12 will be synthesized by a coupling and cyclization reaction of acylated phloroglucinol 
and an acid chloride through a Baker–Venkataraman rearrangement. The acylated phloroglucinol 
will be synthesized via a Friedel-Crafts C-acylation with an aliphatic acid chloride to create a 
ketone, whereas, the second fragment used for coupling will either be commercially available or 
synthesized from a carboxylic acid. Additionally, the carboxylic acid will be created by ester 
hydrolysis of a tri-protected phenolic compound, where the latter will be synthesized by 
benzylating three alcohols.  
 The same design strategy will be used to create the trifluoromethylated derivatives 4–12. 
However, we will need to synthesize trifluoromethylated acid chlorides that can be attached to 
O
O
HO
OH
OR2
OR1
OR1
OR1
R1 = 
benzyl: 1, 4, 7, and 10 
H: 2, 5, 8, and 11
methyl: 3, 6, 9, and 12
R2 = 
-CH3: 1–3
-CH2CF3: 4–6
-C(CF3)2CH3: 7–9 
-CH(CF3)2: 10–12
 9 
phloroglucinol. This will be followed by the same synthetic steps done for the previous 
compounds. 
 
 
Scheme 2. Retrosynthetic design of the 3-methoxyflavone derivatives. 
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2. RESULTS AND DISCUSSION 
 The synthesis of compounds 14 and 15 was successful with a 66% yield (Scheme 3). 
However, when attempting to synthesize compound 18 using Friedel-Crafts acylation, the 
reaction conditions seen in entry 1 (Table 3) had to be optimized to get the ketone 18 as a major 
product instead of an ester. After numerous trials, the best conditions to obtain the ketone 18 as 
the major thermodynamic product with the fewest side products are in entry 13. The purification 
by flash column chromatography was difficult, in which many different mixtures of hexane/ethyl 
acetate/acetic acid were required. Recrystallization attempts in different solvents were also 
unsuccessful. However, the best separation using flash column chromatography was observed 
when dichloromethane/ethanol/acetic acid were used in a 95:5:1 ratio.  
 
 
Scheme 3. Synthesis of the 3-methoxyflavone derivatives 1 and 2.           
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Table 3. Friedel-Crafts acylation of phloroglucinol 16. 
 
Entry Conditions Comments 
1a CH2Cl2 / Et2O, AlCl3 (1.3 equiv), 50 °C, 24 hrs Ester is the major product 
2 a CH2Cl2 / Et2O, AlCl3 (1.3 equiv), 33 °C, 24 hrs Side products 
3 a CH2Cl2 / Et2O, AlCl3 (1.3 equiv), 33 °C/ reflux, 6 hrs Side products 
4 a CH2Cl2 / THF, AlCl3 (1.3 equiv), 36 °C, 24 hrs Ester is the major product 
5 a CH2Cl2 / dioxane, AlCl3 (1.3 equiv), 36 °C, 24 hrs Side products 
6 b CH2Cl2 / THF, AlCl3 (1.3 equiv), 50 °C, 25 hrs Ester is the major product, sealed tube 
7 b CH2Cl2 / dioxane, AlCl3 (1.3 equiv), rt, > 7 days Slow, side products 
8 b CH2Cl2 / dioxane, AlCl3 (2 equiv), 70 °C, 5 days More ester observed, new side products, sealed tube 
9 b CH2Cl2 / dioxane, AlCl3 (2 equiv), 100 °C, 6 days More ester observed, new side products, sealed tube 
10 c CH2Cl2 / dioxane, AlCl3 (4 equiv), 35 °C, > 7 days More concentrated, side products, sealed tube 
11 c CH2Cl2 / dioxane, AlCl3 (3 equiv), 35 °C, > 7 days More concentrated, side products, sealed tube 
12 b CH2Cl2 / dioxane, AlCl3 (1.3 equiv), 35 °C, > 7 days Good conditions, sealed tube 
13 b CH2Cl2 / dioxane, AlCl3 (3 equiv), 35 °C, > 7 days Best conditions, sealed tube 
14 b CH2Cl2 / dioxane, FeCl3 (3 equiv), 35 °C, 3 days No reaction, sealed tube 
15 b CH2Cl2 / dioxane, ZnCl2 (3 equiv), 35 °C, 3 days No reaction, sealed tube 
All entries: 1 equivalent of phloroglucinol 16. 
a 0.9 equivalents of the acid chloride 17. 
b 1 equivalent of the acid chloride 17. 
c 1.5 equivalents of the acid chloride 17. 
 
 After the conversion of the carboxylic acid 15 into the acid chloride 19, coupling and 
cyclization in a single step was attempted from the ketone 18 and the acid chloride 19 (Scheme 
3). There are numerous procedures to cyclize these polyhydroxylated flavones, like the ones seen 
in the Quye 19, Lee 9, Porco 20, Barron 21, De Groot 22, Kim 23, Silakari 24, Lee 25, Pietro 26 labs, 
and many others. Such a variety in synthetic methods may indicate the difficulty of the 
cyclization, because there is no uniform method to achieve it. We tried direct cyclization to 
OH
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54%
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synthesize flavone 1 by using the ketone 18 and the benzoyl chloride 19. In the first trial, 
toluene, one equivalent of TBAHS, and two equivalents of K2CO3 were used at 90 °C. Next, we 
tried the same conditions, but we used KOH instead of K2CO3. Both trials were unsuccessful, 
providing coupled intermediates rather than the cyclized flavone 1. The same attempts were 
made to synthesize the trimethoxylated 3-methoxyflavone 3. The ketone 18 was reacted with the 
trimethoxy benzoyl chloride derivative 20. However, no cyclization was achieved after trials 
with different conditions and reagents (Table 4).  
 
Table 4. Coupling and cyclization attempts of compound 18 with 20. 
 
Entry Conditions Comments 
1a toluene, TBAHS (1 equiv), K2CO3 (2 equiv), 90 °C, 24 hrs 
No 
cyclization 
2 a toluene, TBAHS (1.5 equiv), K2CO3 (4 equiv), reflux, 9 hrs 
3 a toluene, TBAHS (1 equiv), KOH (2 equiv), 90 °C, 24 hrs 
4 a toluene, KOH (2 equiv), 90 °C, 24 hrs 
5 a pyridine, K2CO3 (5 equiv), rt for 24 hrs, then 150 °C for 2 hrs 
6 b ethyl acetate/ acetone, Et3N (3.5 equiv) 5% KOH in MeOH, reflux for 2 hrs, then rt for 24 hrs 
7 b ethyl acetate/ acetone, Et3N (3.5 equiv) 5% KOH in MeOH, 20% FeCl3, reflux for 2 hrs, then rt for 
24 hrs 
8 b THF, Et3N (3.5 equiv) 5% KOH in MeOH, reflux, 9 hrs 
All entries: 1 equivalent of 18. 
a 2 equivalents of the acid chloride 20. 
b 3 equivalents of the acid chloride 20. 
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 Next, we decided to protect the three hydroxyl groups on the ketone 18 to create the tri-
esterified compound 21 prior to cyclization (Scheme 4). The protection was successful, but the 
cyclization using NaH and sodium acetate was not successful. Another attempt using 5% KOH 
in methanol did not succeed. In other trials, bases like KHMDS or NaH were used and unwanted 
intermediates were formed. 
 
 
Scheme 4. Synthesis of the 3-methoxyflavone derivative 3 by global esterification of triphenol 
18. 
 
 Next, a similar approach was undertaken but a different protecting group was used. In 
this strategy, the three hydroxyls in the ketone 18 were protected using TBDPSCl, and the 
resultant compound 24 would be reacted with the trimethoxy benzoyl chloride derivative 20, to 
provide the diketone 25 (Scheme 5). Reaction conditions were screened to achieve tri-protection 
(Table 5). Phloroglucinol 16 and the ketone 18 were used as starting materials, in which the 
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 14 
former was used to get optimized conditions for the latter. The reaction was significantly 
affected by the solvent used, and acetonitrile was the solvent of choice. However, the attempt to 
synthesize the diketone 25 using NaH and CH2Cl2 in the following step was not successful. 
 
 
Scheme 5. Synthesis of the 3-methoxyflavone derivative 3 by global silylation of triphenol 18. 
 
Table 5. Tri-protection of compounds 16 and 18 using TBDPSCl as a protecting group. 
 
Entry Conditions Comments 
1 acetone/CH2Cl2, 18, rt, 3 days No reaction 
2 THF, 18, 0 °C to rt, 48 hrs No reaction 
3 THF, 16, rt, 24 hrs No reaction 
4  dioxane, 16, rt, 24 hrs No reaction 
5 CH2Cl2, 16, rt, 3 days 37% 
6 acetonitrile, 16, rt, 3 days 65% 
7 acetonitrile, 18, rt, 3 days 90% 
All entries: 1 equivalent of compounds 18 and 16, 3.6 equivalents of TBDPSCl, 15 equivalents of Et3N, and 0.7 equivalents of DMAP. 
 
 
O
Cl
O
O
OOH
OHHO
O
O
O
O
OH
O
O
O
O
HO
+
O
OO
O
O
TBDPS
TBDPS TBDPS
O
O
O
O
O
O
O
O
O
TBDPS
TBDPS
TBDPS
O
O
O
O
OH
OH
HO
O
O
Ph
Si
Ph
Cl
18
23
24 20
25263
acetonitrile, DMAP,
 rt, 3 days
90%
Et3N
OH
OHHO
O
OPh
Si
Ph
Cl
18
23OH
OHHO
16
O
OO
O
O
O
OO
TBDPS
TBDPSTBDPS
TBDPS
TBDPS TBDPS
or
2427
Ph
Si
Ph
Cl
23
 15 
 The next step was to deprotect one of the ortho hydroxyl groups in compound 24, prior to 
coupling with the trimethoxy benzoyl chloride derivative 20 (Scheme 6). The coupled 
intermediate 29 would then be rearranged, cyclized, and deprotected to give the flavone 3. 
Attempts to deprotect only one hydroxyl group were carried out using compounds 24 and 27. 
Trials with 0.3 and 1 equivalents of TBAF gave the completely deprotected phloroglucinol 16 
and the ketone 18. However, when acetic acid was added to the reaction, a mixture of mono-
protected, di-protected, and tri-protected products were observed. 
 
 
Scheme 6. Synthesis of the 3-methoxyflavone derivative 3 by global silylation of triphenol 18, 
followed by deprotection of one OH group. 
 
 The synthetic strategy was further modified (Scheme 7) to yield compound 28 in much 
higher amounts than the ones seen in the previous approach. Herein, compound 28 was 
synthesized by protecting only two hydroxyl groups on the ketone 18 instead of protecting three 
and then deprotecting one. The reaction should be carefully monitored by TLC to avoid having 
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the tri-protected product 24 as the major product, as many trials provided varying results (Table 
6).  It was observed that the number of equivalents of TBDPSCl is more important in 
determining the extent of protection than the number of equivalents of the base. At room 
temperature, at least 4 equivalents of the base and 2.5 equivalents of TBDPSCl are needed to 
achieve di-protection of phloroglucinol 16. The reaction is better controlled without DMAP and 
when the reagents are gradually added. No condition gave the di-protected compound 32 as a 
sole product. In the next step, the coupling of compounds 28 to 20 was successful producing the 
ester 29, and its structure was characterized by several NMR experiments (Table 7).  
 
 
Scheme 7. Synthesis of the 3-methoxyflavone derivative 3 by di-protecting compound 18 with 
TBDPS protecting groups. 
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Table 6. Di-protection of compound 16 using TBDPSCl as a protecting group. 
 
Entry Conditions Comments 
1 acetonitrile, TBDPSCl (2 equiv), Et3N (15 equiv), DMAP (0.7 equiv), rt, 48 hrs Mono-protection is 
major 
2 acetonitrile, TBDPSCl (2.5 equiv), Et3N (15 equiv), DMAP (0.7 equiv), rt to 70 °C, 48 hrs 
/ 24 hrs 
Mono-protection is 
major 
3 acetonitrile, TBDPSCl (3 equiv), Et3N (15 equiv), DMAP (0.7 equiv), rt to 70 °C, 48 hrs / 
24 hrs 
Mixture 
4  acetonitrile, TBDPSCl (2.5 equiv), Et3N (4 equiv), DMAP (0.7 equiv), rt to 70 °C, 48 hrs / 
24 hrs 
Mixture 
5 acetonitrile, TBDPSCl (2.5 equiv), Et3N (3 equiv), DMAP (0.7 equiv), rt to 70 °C, 48 hrs / 
24 hrs 
Mono-protection only 
6 acetonitrile, TBDPSCl (2.5 equiv), Et3N (2.5 equiv), DMAP (0.7 equiv), rt to 70 °C, 48 
hrs / 24 hrs 
Mono-protection only 
7 CH2Cl2, TBDPSCl (2.5 equiv), Et3N (2.5 equiv), rt, 24 hrs Mixture 
8 CH2Cl2, TBDPSCl (2.5 equiv), Et3N (4 equiv), rt, 24 hrs Di-/tri-protection 
9 CH2Cl2, TBDPSCl (2.5 equiv), Et3N (15 equiv), rt, 24 hrs Mono-protection only 
10 acetonitrile, TBDPSCl (2.5 equiv), Et3N (2.5 equiv), rt, 24 hrs Mixture 
11 acetonitrile, TBDPSCl (2.5 equiv), Et3N (4 equiv), rt, 24 hrs Mixture 
12 acetonitrile, TBDPSCl (2.5 equiv), Et3N (15 equiv), rt, 24 hrs Di-/tri-protection 
All entries: 1 equivalent of compound 16. 
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Table 7. DEPT and HSQC experiments of compound 29. 
DEPT Experiment # of C signals # of CH signals # of CH2 signals # of CH3 signals 
13C 13 9 1 5 
DEPT-90 0 9 0 0 
DEPT-135 0 9 (up) 1 (down) 5 (up) 
DEPTQ-135 13 (down) 9 (up) 1 (down) 5 (up) 
HSQC 
 
1H-13C resonance 1H chemical shift 13C chemical shift 
Ha-Ca 0.89 26.32 
Hb-Cb 0.98 26.36 
Hc-Cc 3.39 59.25 
Hd-Cd 3.91 56.29 
He-Ce 3.94 60.92 
Hf-Cf 4.57 78.36 
Hg-Cg 7.39 107.55 
Hh-Ch 6.46 108.09 
Hi-Ci 5.92 109.00 
Hj-Cj 7.19 127.72 
Hk-Ck 7.27 127.90 
Hl-Cl 7.32 129.83 
Hm-Cm 7.37 130.06 
Hn-Cn 7.37 135.11 
Ho-Co 7.51 135.16 
CDCl3 400 MHz, see appendix for spectra. 
 
 Several attempts were used to synthesize 3-methoxyflavone 3 from the ester 29 (Table 8). 
In a three-step synthesis, the ester 29 was rearranged using NaH giving the diketone 30, cyclized 
h
O
O
f
O
O
c
Si
Si
g
g
O
O
O
O
O
e
d
d b
aa
a
o k
m
koo
k
m
k
ob
b
n
j
l j
n
n
j
l
j
n
i
 19 
by adding sodium acetate and acetic acid to give the protected flavone 31, and then deprotected 
to give the final 3-methoxyflavone 3. Trials with K2CO3 or DBU with pyridine were successful, 
having three steps in a single reaction; rearrangement to the diketone, cyclization, and 
deprotection. To purify the 3-methoxyflavone 3, recrystallization using different solvents was 
unsuccessful. The compound was partially purified by using prep TLC with a mixture of 
ammonium hydroxide: dichloromethane: methanol in a ratio of 1: 90: 9, further purification is 
still needed. The structure was confirmed with mass spectrometry and 1H and 13C NMR.  
 
Table 8. Cyclization and deprotection of compound 29 to synthesize compound 3. 
 
Entry Conditions Comments 
1 a) NaH, THF, reflux for 90 mins 
b) NaOAc, AcOH, reflux for 8 hrs 
c) TBAF, THF, 0°C to rt, 27 hrs 
a) product is the diketone 30 
b) product is the protected flavone 31 
c) product is the flavone 3 
2 K2CO3, pyridine, reflux for 13 hrs Product is the flavone 3, some of 31 remain 
3 DBU, pyridine, reflux for 11 hrs Product is the flavone 3, best conditions 
4  pyridine, reflux for 16 hrs Partial cyclization 
All entries: 1 equivalent of compound 29. 
 
 Synthesis of the trifluoromethylated derivatives has been challenging as well (Scheme 8). 
In the first step, bromoacetic acid 33 is attached to trifluoromethylated alcohols 34–36 to 
generate an ether linkage. Trifluoroethanol 34, hexafluoro-tert-butanol 35, or 
hexafluoroisopropanol 36 were used as alcohols, in the presence of sodium hydride (60% in 
mineral oil), bromoacetic acid, and THF (Table 9). Most of the attempts were unsuccessful, 
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except for entry 10, in which potassium carbonate was used as a base and acetone was used as a 
solvent. These conditions were used to synthesize compounds 37 and 39. The structures of the 
crude products were confirmed by 1H and 13C NMR. The splitting pattern in the latter, caused by 
the presence of fluorine atoms and changes in chemical shifts, confirmed the successful 
attachment of bromoacetic acid with the trifluoroethanol 34 and the hexafluoroisopropanol 36. In 
the future, using 4–10 equivalents of sodium hydride may also be attempted. 
 
 
Scheme 8. Synthesis of the trifluoromethylated 3-methoxyflavone derivatives 4–12. 
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Table 9. Synthesis of the trifluoromethylated carboxylic acids 37–39. 
 
Entry Conditions Comments 
1 34, THF, NaH (1.2 equiv), reflux, 7 hrs No reaction 
2 34, THF, NaH (1.7 equiv), 0 °C to rt, 48 hrs No reaction 
3 34, THF, NaH (1.2 equiv), 63 °C, 24 hrs No reaction, sealed tube 
4 34, THF, NaH (1.2 equiv), 0 °C to rt, 24 hrs No reaction, sealed tube 
5 36, THF, NaH (1.2 equiv), rt for 19 hrs, then 48 °C for 6 hrs No reaction 
6 35, THF, NaH (1.2 equiv), rt for 19 hrs, then 50 °C for 6 hrs No reaction 
7 36, THF, NaH (1.2 equiv), rt for 6 hrs, then reflux for 6 hrs No reaction 
8 35, THF, NaH (1.2 equiv), rt for 6 hrs, then reflux for 6 hrs No reaction 
9 36, acetone, 85% KOH in H2O (2.1 equiv), rt for 24 hrs, then reflux for 12 hrs No reaction 
10 36, acetone, K2CO3 (2.55 equiv), rt for 24 hrs, then reflux for 12 hrs Success 
All entries: 1 equivalent of 33 and 1.5 equivalents of the trifluoromethylated alcohols. 
 
 Next, the carboxylic acid 39 was converted into the acid chloride 42, and then used in 
Friedel-Crafts acylation to produce the ketone 45. The acid chloride 42 was poorly soluble in the 
solvents used in the reaction, i.e. dichloromethane and dioxane. The crude 13C NMR of the 
ketone 45 showed a successful conversion; however, the ester side product was also present. We 
are attempting to redo these two steps by using the carboxylic acid 37 and optimize the 
conditions when needed.  
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3. CONCLUSION AND FUTURE DIRECTIONS 
 The synthesis of the polyhydroxylated 3-methoxyflavones appears to be challenging. 
However, we were able to optimize a synthetic scheme that can be valuable to synthesize all 
derivatives. The use of silyl protecting groups was essential. Moreover, three steps, the 
rearrangement to the diketone, the cyclization, and the deprotection, were achieved using a single 
reaction, i.e. the DBU-catalyzed cyclization reaction. The compounds will then be sent for 
testing for their neuroprotective properties. They will also be assessed for their antioxidant 
properties, in which their utility as 19F NMR probes for quantitative analysis of their radical 
scavenging abilities will be explored. 
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4. EXPERIMENTAL DETAILS 
 
Methyl 3,4,5-tris(benzyloxy)benzoate 14.27 Methyl gallate 13 (200 mg, 1 mmol), potassium 
iodide (79 mg, 0.48 mmol), and potassium carbonate (880 mg, 6.4 mmol) were mixed in acetone 
(12 mL). Benzyl bromide (0.41 mL, 3.5 mmol) in acetone (2 mL) was added to the reaction 
flask, and the mixture was refluxed for 7 hours. The mixture was then filtered through celite by 
using ethyl acetate (20 mL) and evaporated to produce a pale-yellow solid material. The crude 14 
was used in the next step without purification. 
 
 
3,4,5-Tris(benzyloxy)benzoic acid 15.27 A suspension of crude methyl 3,4,5-
tris(benzyloxy)benzoate 14 (628 mg) and sodium hydroxide (88 mg, 2.2 mmol) in ethanol (10.6 
mL) was refluxed for 6 hours. The reaction was quenched with hydrochloric acid (10.6 mL, 1 M) 
and stirred for 10 minutes. The reaction was then filtered and washed successively with ethanol: 
water (5:5 mL), water (10 mL), ethanol (10 mL), methanol (10 mL), then diethyl ether (10 mL). 
The crude compound 15 was recrystallized from ethanol to give colorless crystals (316 mg) in 
66% yield: 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 7.1 Hz, 6H), 7.38 (t, J = 7.2 Hz, 6H), 7.33 
(t, J = 6.9 Hz, 3H), 7.24 (s, 2H), 5.14 (s, 4H), 5.13 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 171.5, 
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152.6, 142.9, 137.3, 136.5, 128.7, 128.3, 128.2, 128.2, 127.6, 124.2, 109.3, 75.2, 71.1. 
 
 
2-Methoxy-1-(2,4,6-trihydroxyphenyl)ethan-1-one 18.20 Aluminum chloride (317 mg, 2.38 
mmol) was mixed in a sealed tube with dichloromethane (1 mL) at  −10 °C. A mixture of 
benzene-1,3,5-triol 16 (100 mg, 0.8 mmol) in dioxane (0.5 mL) was added to the reaction and 
stirred at −10 °C for 30 minutes. Another mixture of 2-methoxyacetyl chloride (0.07 mL, 0.8 
mmol) in dichloromethane (0.3 mL) was added dropwise to the reaction, and the reaction was 
warmed to room temperature then heated at 35 °C for about a week. The reaction was cooled and 
quenched with hydrochloric acid (0.75 mL, 1 M). Then it was extracted with ethyl acetate (5 
mL), water (2 mL), and brine (1 mL). Washing with ethyl acetate was repeated until the solvent 
was colorless. The compound was dried over sodium sulfate, filtered, and evaporated to yield an 
orange crude solid. The reaction was purified by silica flash column chromatography using 
ethanol: dichloromethane: acetic acid (5:95:1) to give the pure yellow compound 18 (84 mg) in 
54% yield: 1H NMR (400 MHz, (CD3)2CO) δ 6.02 (s, 2H), 4.74 (s, 2H), 3.50 (s, 3H); 13C NMR 
(100 MHz, DMSO) δ 201.3, 165.0, 164.1, 102.4, 94.5, 77.1, 58.5. 
 
 
3,4,5-Tris(benzyloxy)benzoyl chloride 19.27 To a solution of 3,4,5-tris(benzyloxy)benzoic acid 
15 (118 mg, 0.268 mmol) in toluene (1.7 mL), DMF (5.2 µL) was added, and the reaction was 
stirred at room temperature. A solution of oxalyl chloride (0.04 mL, 0.4 mmol) in toluene (0.36 
OH
OHHO
Cl
O
OAlCl3
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 25 
mL) was added to the reaction mixture and the mixture was stirred for 20 minutes at room 
temperature. The reaction was then heated at 50 °C for two hours, then evaporated to yield a 
pale-yellow crude solid 19, which was used in the next step immediately. 
 
 
2-(2-Methoxyacetyl)benzene-1,3,5-triyl tris(3,4,5-trimethoxybenzoate) 21.25 A solution of 2-
methoxy-1-(2,4,6-trihydroxyphenyl)ethan-1-one 18 (20 mg, 0.1 mmol) in pyridine (0.16 mL) 
and dichloromethane (0.5 mL) was prepared at 0 °C. 3,4,5-Trimethoxybenzoyl chloride 20 (93 
mg, 0.40 mmol) and DMAP (5 mg, 0.04 mmol) were then added to the solution and the reaction 
was stirred for three days at 30 °C. The reaction was then quenched with NaHCO3 (2 mL) and 
HCl (1 mL, 1 M). The compound was then extracted with dichloromethane (5 mL × 3) and 
washed with brine (0.3 mL). The organic layer was dried over sodium sulfate, filtered, and then 
evaporated to give a crude orange solid 21, which was used in the next step without purification. 
 
 
2-Methoxy-1-(2,4,6-tris((tert-butyldiphenylsilyl)oxy)phenyl)ethan-1-one 24.28 A mixture of 
2-methoxy-1-(2,4,6-trihydroxyphenyl)ethan-1-one 18 (28 mg, 0.14 mmol) and DMAP (12 mg, 
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0.10 mmol) was prepared and charged with argon at 0 °C. TBDPSCl 23 (0.13 mL, 0.51 mmol), 
Et3N (0.29 mL, 2.1 mmol), and acetonitrile (3 mL) were added to the flask at 0 °C. The mixture 
was stirred at room temperature for three days. The reaction mixture was quenched with NH4Cl 
(3 mL). The mixture was extracted with dichloromethane (8 mL × 3) and washed with brine (1 
mL). The organic layer was dried over sodium sulfate, filtered, and then evaporated to give a 
crude orange oil. The mixture was purified by silica flash column chromatography using hexane: 
ethyl acetate in a ratio of 92:8 to give a pure colorless solid 24 (80 mg) in 90% yield: 1H NMR 
(400 MHz, CDCl3) δ 7.51 (d, J = 8 Hz, 8H), 7.34 (t, J = 7.4 Hz, 4H), 7.24–7.19 (m, 10H), 7.04–
6.98 (m, 8H), 5.50 (s, 2H), 4.45 (s, 2H), 3.47 (s, 3H), 0.96 (s, 18H), 0.61 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ 201.9, 156.8, 153.7, 135.5, 135.1, 132.3, 132.1, 130.0, 129.6, 127.9, 127.5, 
115.9, 105.0, 79.0, 59.7, 26.5, 26.4, 19.5, 19.3. 
 
 
1,3,5-Tris((tert-butyldiphenylsilyl)oxy)benzene 27.28 A mixture of benzene-1,3,5-triol 16 (20 
mg, 0.2 mmol) and DMAP (14 mg, 0.11 mmol) was prepared and charged with argon at 0 °C. 
TBDPSCl 23 (0.15 mL, 0.57 mmol), Et3N (0.30 mL, 2.4 mmol), and acetonitrile (2 mL) were 
added to the flask at 0 °C. The mixture was stirred at room temperature for three days. The 
reaction mixture was quenched with NH4Cl (1 mL), extracted with dichloromethane (6 mL × 3), 
and washed with brine (1 mL). The organic layer was dried over sodium sulfate, filtered, and 
then evaporated to give a crude orange oil. The mixture was purified by silica flash column 
chromatography using hexane: ethyl acetate in a ratio of 97:3 to give a pure colorless solid 27 
(87 mg) in 65% yield: 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 6 Hz, 12H), 7.40 (t, J = 8 Hz, 
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6H), 7.30 (s, 6H), 7.28 (s, 6H), 5.88 (s, 3H), 0.99 (s, 27H); 13C NMR (100 MHz, CDCl3) δ 156.5, 
135.5, 133.0, 129.7, 127.7, 105.7, 26.7, 19.5. 
 
1-(2,4-Bis((tert-butyldiphenylsilyl)oxy)-6-hydroxyphenyl)-2-methoxyethan-1-one 28.29 To 2-
methoxy-1-(2,4,6-trihydroxyphenyl)ethan-1-one 18 (25 mg, 0.13 mmol) charged with argon, 
acetonitrile (3 mL) was added. TBDPSCl 23 (82 µL, 0.32 mmol) and Et3N (70 µL, 0.5 mmol) 
were added over 90 minutes. The reaction mixture was stirred at room temperature for 24 hours. 
The TLC showed minor conversion into the di-protected product, so more TBDPSCl 23 was 
added (80 µL, 0.3 mmol) gradually, until the desired compound was a major product. The 
reaction mixture was quenched with 1% HCl (3 mL) and extracted with dichloromethane (5 mL 
× 3). The organic layer was dried over sodium sulfate, filtered, and then evaporated to give a 
crude yellow oil. To remove most impurities from the crude product, it was partially purified 
using a mixture of hexane: ethyl acetate: acetic acid in a ratio of 92: 8: 1, to give the di-protected 
compound 28 and TBDPSOH as a yellow oil. The product 28 was used in the next step without 
further purification. 
 
 
3,5-Bis((tert-butyldiphenylsilyl)oxy)-2-(2-methoxyacetyl)phenyl 3,4,5-trimethoxybenzoate 
29.20 The crude product of 1-(2,4-bis((tert-butyldiphenylsilyl)oxy)-6-hydroxyphenyl)-2-
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 28 
methoxyethan-1-one 28 (1.826 g, 2.705 mmol), DMAP (165 mg, 1.35 mmol), and 3,4,5-
trimethoxybenzoyl chloride 20 (624 mg, 2.71 mmol) were added to the reaction flask and 
charged with argon at 0 °C. Dichloromethane (20 mL) and Et3N (0.75 mL, 5.4 mmol) were 
added to the reaction flask and stirred at 0 °C for one hour. The reaction was then stirred at room 
temperature for 24 hours and quenched with 1% HCl (20 mL). Ethyl acetate was added to the 
mixture (20 mL) and the organic layer was separated. The aqueous layer was extracted with ethyl 
acetate (20 mL × 3), and the combined organic layers were dried over sodium sulfate, filtered, 
and then evaporated to give a crude yellow oil. The mixture was purified by silica flash column 
chromatography using hexane: ethyl acetate in a ratio of 8: 2, to give the pure yellow oil 29 (460 
mg) in 17% yield over three steps:1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 6.9 Hz, 4H), 7.26 
(s, 2H), 7.24 (d, J = 6.7 Hz, 6H), 7.20 (s, 1H), 7.18 (s, 1H), 7.14 (t, J = 7.4 Hz, 4H), 7.06 (t, J = 
7.5 Hz, 4H), 6.33 (d, J = 2.0 Hz, 1H), 5.79 (d, J = 2.0 Hz, 1H), 4.44 (s, 2H), 3.81 (s, 3H), 3.78 (s, 
6H), 3.26 (s, 3H), 0.85 (s, 9H), 0.76 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 199.8, 164.0, 157.5, 
154.2, 153.0, 149.2, 143.0, 135.1, 135.0, 131.7, 131.1, 130.0, 129.8, 127.8, 127.6, 123.8, 117.1, 
108.9, 108.0, 107.4, 78.3, 60.8, 59.2, 56.2, 26.3, 26.2, 19.2, 19.2. 
 
 
5,7-Dihydroxy-3-methoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one 3.29 To 3,5-
bis((tert-butyldiphenylsilyl)oxy)-2-(2-methoxyacetyl)phenyl 3,4,5-trimethoxybenzoate 29 (376 
mg, 0.433 mmol) charged with argon, pyridine (1.3 mL) and DBU (0.30 mL, 2.2 mmol) were 
29 3
OH
HO
O
O O
O
O
O
O
O
O
OTBDPS
TBDPS
O
O
O
O
O
DBU, pyridine
reflux for 11 hrs
 29 
added. The reaction mixture was refluxed for 11 hours. Then, it was quenched with NH4Cl (3 
mL), extracted with ethyl acetate (10 mL × 3), dried over sodium sulfate, filtered, and evaporated 
to give a crude dark orange solid. The compound was partially purified by using silica gel 
preparative TLC with a mixture of ammonium hydroxide: dichloromethane: methanol in a ratio 
of 1: 90: 9, to give a yellow oil 3: 1H NMR (400 MHz, (CD3)2CO) δ 12.68 (s, 1H), 7.44 (s, 2H), 
6.52 (d, J = 2.0 Hz, 1H), 6.27 (d, J = 2.0 Hz, 1H), 3.87 (s, 9H), 3.83 (s, 3H); 13C NMR (100 
MHz, (CD3)2CO) δ 177.1, 166.3, 163.1, 157.8, 154.2, 154.1, 141.7, 140.0, 126.5, 107.2, 105.6, 
99.6, 94.7, 60.6, 56.7, 56.5; MS (ESI) m/z calcd for C19H18O8 (M)+ 374.10, found 374.15. 
 
 
2-(2,2,2-Trifluoroethoxy)acetic acid 37.30 2-Bromoacetic acid 33 (1500 mg, 11 mmol) and 
potassium carbonate (3805 mg, 27.53 mmol) were charged with argon. 2,2,2-Trifluoroethan-1-ol 
34 (1.17 mL, 16.2 mmol) and acetone (15 mL) were added to the reaction flask and stirred at 
room temperature for 24 hours. The reaction mixture was then refluxed for 12 hours. After 
cooling, the mixture was quenched with concentrated HCl (2.1 mL), extracted with 
dichloromethane (15 mL × 3), dried over sodium sulfate, filtered, and then evaporated to give a 
crude yellow solid. The compound 37 was used in the next step without purification. 
 
 
2-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)acetic acid 39.31 2-Bromoacetic acid 33 (250 mg, 
1.8 mmol) and potassium carbonate (634 mg, 4.59 mmol) were charged with argon. 1,1,1,3,3,3-
HO
O
Br HO CF3
+
K2CO3, acetone
rt for 24 hrs, then
reflux for 12 hrs
HO
O
CF3O
33 34 37
HO
O
Br F3C CF3
OH
+
K2CO3, acetone
rt for 24 hrs, then
reflux for 12 hrs
HO
O
CF3
CF3O
33 36 39
 30 
Hexafluoropropan-2-ol 36 (0.28 mL, 2.7 mmol) and acetone (3 mL) were added to the reaction 
flask and stirred at room temperature for 24 hours. The reaction mixture was then refluxed for 12 
hours. After cooling, the mixture was quenched with concentrated HCl (0.35 mL), extracted with 
dichloromethane (3 mL × 3), dried over sodium sulfate, filtered, and then evaporated to give a 
crude brown solid. The compound 39 was used in the next step without purification. 
 
 
2-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)acetyl chloride 42.27 To a solution of 2-
((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)acetic acid 39 (186 mg, 0.823 mmol) in toluene (2.7 
mL), DMF (8 µL) was added, and the reaction was stirred at room temperature. A solution of 
oxalyl chloride (0.11 mL, 1.2 mmol) in toluene (1.1 mL) was added to the reaction mixture and 
the mixture was stirred for 20 minutes at room temperature. The reaction was then heated at 50 
°C for three hours, then evaporated to yield a brown crude oil 42, which was used in the next 
step immediately. 
 
 
2-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)-1-(2,4,6-trihydroxyphenyl)ethan-1-one 45.20 
Aluminum chloride (178 mg, 1.34 mmol) was mixed in a sealed tube with dichloromethane (0.8 
mL) at  −10 °C. A mixture of benzene-1,3,5-triol 16 (56 mg, 0.45 mmol) in dioxane (0.3 mL) 
was added to the reaction and stirred at −10 °C for 30 minutes. Another mixture of 2-
((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)acetyl chloride 42 (109 mg, 0.446 mmol) in 
HO
O
O
oxalyl chloride
toluene, DMF
3 hrs at 50 °C
Cl
O
OCF3 CF3
CF3 CF339 42
O
O
OH
HO OH
AlCl3,
CH2Cl2, dioxane, 
at 35°C, 7 days
CF3
CF3
Cl
O
O
OH
HO OH
+CF3
CF3
42 16 45
 31 
dichloromethane (1 mL) was added dropwise to the reaction, and the reaction was warmed to 
room temperature then heated at 35 °C for about a week. The reaction was cooled and quenched 
with hydrochloric acid (10 mL, 1 M). Then it was extracted with ethyl acetate (10 mL), water (5 
mL), and brine (2 mL). Washing with ethyl acetate was repeated until the solvent was colorless. 
The compound was dried over sodium sulfate, filtered, and evaporated to yield a brown crude 
solid 45.  
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